Publication: Are bet inhibitors yet promising latency-reversing agents for hiv-1 reactivation in aids therapy?
3
Issued Date
2021-06-01
Resource Type
ISSN
19994915
Other identifier(s)
2-s2.0-85107412559
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Viruses. Vol.13, No.6 (2021)
Suggested Citation
Thanarat Salahong, Christian Schwartz, Rungroch Sungthong Are bet inhibitors yet promising latency-reversing agents for hiv-1 reactivation in aids therapy?. Viruses. Vol.13, No.6 (2021). doi:10.3390/v13061026 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77275
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Are bet inhibitors yet promising latency-reversing agents for hiv-1 reactivation in aids therapy?
Abstract
AIDS first emerged decades ago; however, its cure, i.e., eliminating all virus sources, is still unachievable. A critical burden of AIDS therapy is the evasive nature of HIV-1 in face of host immune responses, the so-called “latency.” Recently, a promising approach, the “Shock and Kill” strategy, was proposed to eliminate latently HIV-1-infected cell reservoirs. The “Shock and Kill” concept involves two crucial steps: HIV-1 reactivation from its latency stage using a latency-reversing agent (LRA) followed by host immune responses to destroy HIV-1-infected cells in combination with reinforced antiretroviral therapy to kill the progeny virus. Hence, a key challenge is to search for optimal LRAs. Looking at epigenetics of HIV-1 infection, researchers proved that some bromodomains and extra-terminal motif protein inhibitors (BETis) are able to reactivate HIV-1 from latency. However, to date, only a few BETis have shown HIV-1-reactivating functions, and none of them have yet been approved for clinical trial. In this review, we aim to demonstrate the epigenetic roles of BETis in HIV-1 infection and HIV-1-related immune responses. Possible future applications of BETis and their HIV-1-reactivating properties are summarized and discussed.